Ablynx has expanded in the USA, with a subsidiary company, Ablynx Inc., as it has appointed Daniel Schneider as the General Manager to lead the commercialisation of caplacizumab in North America, who will be based in a US office. The company said in the press release on Monday that the USA office will be located on the East Coast, without disclosing the precise location.
Caplacizumab is the Ablynx’s wholly-owned anti-von Willebrand factor (vWF) Nanobody developed for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).
Dan Schneider has 25 years of experience in establishing and leading the commercial operations for a number of companies in the life sciences industry and has been deeply involved in the successful launch of many pharmaceutical products, including those for orphan indications. Until recently, Dan was the General Manager of the Specialty Pharmaceuticals Business Unit at BTG International Inc. Previously, he held senior commercial roles at a number of life science companies where he developed the commercial strategy and led the sales efforts across all sectors of the business. Dan holds a BSBA from Saint Louis University and an MBA from Washington University in St. Louis.
Dr Edwin Moses, CEO of Ablynx, said thta the establishment of Ablynx, Inc. is an important milestone for the company which confirms the commitment to becoming a fully integrated international biopharmaceutical company.
He said. “We are very pleased that Dan is joining us. He brings many years of experience in setting up commercial organisations and leading multiple successful product launches in the USA. We look forward to joining forces to further develop our commercial infrastructure in preparation of the potential launch of caplacizumab.”
Commenting on his appointment, Schneider added: “I am delighted to join Ablynx at this very important moment as the Company prepares for the potential launch of its first product. I look forward to building and leading the commercial activities in North America and contributing to the growth of the company.”